Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tonix Pharma ( (TNXP) ) has shared an update.
On August 18, 2025, Tonix Pharmaceuticals will host a webcast and conference call to discuss the FDA’s approval of Tonmya for fibromyalgia treatment. This approval marks a significant milestone for the company, potentially enhancing its market position and offering new opportunities for growth in the treatment of central nervous system disorders.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock is supported by strong technical indicators and positive corporate events, including FDA approval and strategic initiatives. However, financial performance and valuation concerns due to ongoing losses and negative P/E ratio weigh down the overall score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative therapies for central nervous system disorders. Their primary product, Tonmya, is aimed at treating fibromyalgia in adults.
Average Trading Volume: 1,329,529
Technical Sentiment Signal: Sell
Current Market Cap: $450.1M
See more insights into TNXP stock on TipRanks’ Stock Analysis page.